Citius Pharma’s LYMPHIR gains permanent J-code for billing

CRANFORD, N.J. - Citius Pharmaceuticals (NASDAQ:CTXR), Inc. and its subsidiary Citius Oncology, Inc. have announced the assignment of a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for their drug LYMPHIR by the Centers for Medicare & Medicaid Services (CMS). The J-code, J9161, will be effective starting April 1, 2025, and will facilitate the billing process for healthcare providers administering LYMPHIR for the treatment of adult patients with Stage I-III relapsed or refractory cutaneous T-cell lymphoma (CTCL).

LYMPHIR, a targeted immune therapy, received FDA approval in August 2024 after demonstrating efficacy in patients who have undergone at least one prior systemic therapy. It is designed to bind and kill cancerous T-cells in the skin, providing a new treatment option for this patient population.

The permanent J-code is expected to streamline the reimbursement process for both commercial and government insurance plans, including VA, DoD, and Medicare, making the drug more accessible to patients. Leonard Mazur, Chairman and CEO of Citius Pharma and Citius Oncology, highlighted the importance of the J-code in supporting patient access and providing coding clarity for physicians. While the stock has experienced significant volatility, showing a -88.5% return over the past year, InvestingPro data reveals analysts maintain a consensus buy recommendation with a $3 price target.

The introduction of the permanent J-code is a significant step for Citius Pharmaceuticals, which focuses on developing and commercializing critical care products. In addition to LYMPHIR, Citius Pharma’s pipeline includes other late-stage product candidates such as Mino-Lok, an antibiotic lock solution, and CITI-002, a topical formulation for hemorrhoids.

As the company continues to navigate the commercialization of LYMPHIR, the new J-code is poised to play a critical role in the treatment’s adoption and availability for patients in need. Investors anticipating the company’s next earnings report should mark February 25, 2025, on their calendars. For deeper insights into Citius Pharmaceuticals’ financial health and growth prospects, including 8 additional ProTips, visit InvestingPro. This news is based on a press release statement from Citius Pharmaceuticals, Inc.

In other recent news, Citius Pharmaceuticals has been making significant moves in their business operations. The biopharmaceutical company recently secured approximately $3 million in gross proceeds from a registered direct offering. The funds raised are planned for general corporate purposes, including the development of the company’s product candidates and other capital needs. The transaction was facilitated by H.C. Wainwright & Co., serving as the exclusive placement agent.

In parallel developments, Citius is preparing for the commercial launch of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma. The company aims to have the product available for patients in the first half of 2025. To support this initiative, Citius has secured commercial supply agreements and completed the production of the first-year launch supply.

These recent developments indicate Citius Pharmaceuticals’ proactive approach in strengthening its financial position and advancing its product pipeline. The company’s other late-stage products include Mino-Lok, an antibiotic lock solution, and CITI-002 (Halo-Lido), a topical treatment for hemorrhoids, both of which have completed successful clinical trials.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.